IMPORTANT INVESTOR ALERT: Goldberg Law PC Announces Securities Class Action Lawsuit Against Amicus Therapeutics, Inc. and Encourages Shareholders to Contact the Firm

Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed in United States District Court, District of New Jersey, against Amicus Therapeutics, Inc. (“Amicus” or the “Company”) (NASDAQ: FOLD), for alleged violations of the federal securities laws. Investors who purchased or otherwise acquired shares between September 15, 2015 and October 1, 2015, inclusive (the “Class Period”), have until December 7, 2015 to file a motion to be appointed as lead plaintiff.

If you are a shareholder who suffered a loss during the Class Period, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 13650 Marina Pointe Dr. Suite 1404, Marina Del Rey, CA 90292, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the complaint, on October 2, 2015, Amicus announced that after meeting with FDA officials, the Company does not anticipate being able to submit a new drug application (NDA) for migalastat, the company's Fabry disease treatment, by the end of the year. When the truth was revealed, shares dropped harming investors.

If you have any questions concerning your legal rights in this case, please immediately contact Goldberg Law PC at 800-977-7401, or visit our website at http://www.Goldberglawpc.com, or email us at info@goldberglawpc.com.

Goldberg Law PC represents shareholders around the world and specializes in securities class actions and shareholder rights litigation.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

View source version on businesswire.com: http://www.businesswire.com/news/home/20151012005872/en/